Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563212 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
A Phase 1 study of Pulmonary Fibrosis, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00563212: Completed Phase 1 study of Pulmonary Fibrosis, sponsored by NYU Langone Health.
NCT00563212 is a Phase 1 study of Pulmonary Fibrosis that has completed, run by NYU Langone Health. The registered enrollment target is 12 participants, below the 888-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00563212, a Phase 1 study of Pulmonary Fibrosis, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which there is no effective treatment. Interferon-gamma is a medication that has been used for other lung diseases to decrease scarring and fibrosis. Studies of interferon-gamma injected under the skin did not show any improvement in survival in patients with IPF. We hypothesize that giving interferon-gamma as a nebulized mist directly into the lungs can affect the immune system in a way that decreases fibrosis.
Conditions Studied
Interventions
- DRUG aerosol interferon-gamma
Study Locations (1)
New York
- Division of Pulmonary & Critical Care Medicine, NYU School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-01 |
| Est. Completion | 2018-12-01 |
| Phase | Phase 1 |
What the finished NCT00563212 record still lists
NCT00563212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 888-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which aerosol interferon-gamma is the first listed.
NCT00563212 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00563212 about?
NCT00563212 is a clinical study titled "A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis". Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which there is no effective treatment. Interferon-gamma is a medication that has been used for other lung diseases to decrease scarring and fibrosis. Studies of interferon-gamma injected under the skin did not show any improvement in s...
What is the current status of trial NCT00563212?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2007-01. Estimated completion is 2018-12-01.
What conditions does trial NCT00563212 study?
This clinical trial studies the following conditions: Pulmonary Fibrosis.
What interventions are being tested in trial NCT00563212?
The interventions under investigation include: aerosol interferon-gamma (DRUG).
Who is sponsoring clinical trial NCT00563212?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00563212 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00563212's enrollment target sits among peer trials
12 22nd of 22 higher than 1 of 22 other Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
RECRUITING · Phase 1
-
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
COMPLETED · Phase 1
-
Advanced Imaging for Pulmonary Fibrosis
RECRUITING · Phase 2
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
FAPI PET for Lung Fibrosis
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia